When Andrew Witty (photo) takes over as CEO in May, he'll be running GlaxoSmithKline from London rather than from the U.S. HQ in Philadelphia as his predecessor Jean-Pierre Garnier did. No significant staff or resources will be relocated, and the company will continue to have a "dual headquarters" in both cities. Witty has been living in the UK as chief of the company's European operations. Report